KRAS and non-small cell lung carcinoma: A first-line trial combining GFH925 plus cetuximab in treating metastatic NSCLC (NCT05756153) is expected to provide further insights into the potential benefits of this combination therapy, and to alert researchers to potential putative mechanisms of resistance that may arise, probably those associated with KRAS G12C amplification.